Table 2.
Monocyte functional changes in CVD.
| Reference | Clinical Model | N= | Monocyte Association |
|---|---|---|---|
| Mazzone [46] |
CAD | 120 | CD11b/CD18 was higher on patients with CAD and PAD compared to controls |
| PAD | 50 | ||
| Control | 200 | ||
| Kassirer [47] |
Ischemic heart disease | 45 | CD11b/CD18 was higher on patients with ischemic heart disease than controls |
| Control | 66 | ||
| Tallone [31] |
CAD (Stable) |
13 | Higher CCR2 and CX3CR1 on classical monocytes in CAD vs. control |
| Control | 14 | ||
| Shantsila [20] |
CAD (Stable) |
53 | Upregulated IL-6 on CM and IM in CAD. TNFα production of LPS-stimulated monocytes over baseline was lower in CAD patients than controls |
| Control | 50 | ||
| Shirai [35] |
CAD | 7 | Higher gene expression of IL-6 and IL-1β in response to LPS/Interferon(IFN)γ |
| Control | 7 | ||
| Williams [37] |
CVD patients |
31 | CD163(M2) lower in CVD, CD86/CD163(M1/M2) ratio higher in CVD |
| Control | 33 | ||
| Chan [45] |
CAD (Stable) |
30 | Increased NF-κb activity and iNOS expression in CAD |
| Control | 30 | Increased monocyte adhesion to human endothelial cells |